Introduction
Crohn's disease [CD] is a chronic disorder of the gastrointestinal [GI] tract that leads to development of bowel damage and impaired gut function. 1, 2 Although CD most frequently affects the ileocaecum, it may involve any portion of the GI tract, from the oral cavity to the anus. Upper GI tract involvement refers to affection of oesophagus, stomach, duodenum, and jejunum, which may occur either isolated [Montreal Classification L4] or together with other CD locations [L-13] . 3 Typical CD-related endoscopic lesions of the oesophagus consist of aphthae, erosions, and ulcers [not related to gastrooesophageal reflux disease]. [4] [5] [6] [7] [8] For gastroduodenal CD, endoscopic findings include apthae, longitudinal/irregular erosions, ulcers, and bamboo-like appearances. [9] [10] [11] [12] The frequency of endoscopic lesions in the upper GI tract has been reported with a large variation. Early studies documented a low prevalence of 0.5-4% of CD patients. [13] [14] [15] However, more recently reported rates have been much higher, ranging from 30% to 75%. 16, 17 Horjus and colleagues systematically assessed newly diagnosed CD patients and observed endoscopic lesions in the upper GI tract in 60 out of 108 examined patients [55%] . 18 These discrepancies regarding prevalence rates of upper GI tract lesions are probably related to: i] non-uniform definitions of CD-related lesions; ii] the use of different diagnostic modalities [radiological examinations in early studies versus endoscopies in later investigations]; iii] differences in the examined patient populations [newly diagnosed patients versus treated patients]; and iv] differences regarding the frequency of upper endoscopy as an initial diagnostic procedure. Current ECCO guidelines recommend-irrespective of the findings at ileo-colonoscopy-further investigations [including upper endoscopy] to assess location and extent of any CD in the upper GI tract. 1 In clinical practice, however, such investigation for mapping disease extent is not regularly performed at CD diagnosis except for symptoms that are suggestive for upper GI tract involvement. 19 This is mostly attributed to the fact that the evidence level for this particular ECCO recommendation is weak [evidence level 5, expert opinion] and the grade of recommendation is low [D] . 20 Previous studies on upper GI tract involvement have been limited by the small number of patients or by a cross-sectional study design. [21] [22] [23] As of yet, the frequency of upper GI tract involvement, its risk factors, and its impact on future disease course have not been systematically assessed in a large, nationwide IBD cohort from a cross-sectional and longitudinal perspective. It remains further unknown whether the increasing use of upper endoscopies and antitumour necrosis factor [TNF] treatment have changed the landscape and outcome of upper GI tract involvement. Given this current lack of knowledge, we launched this study using data from the nationwide Swiss Inflammatory Bowel Disease Cohort Study [SIBDCS] to answer the following questions. 1] What is the prevalence of upper GI tract involvement in the SIBDCS? 2] What are associated risk factors that predict such involvement? 3] Is involvement of the upper GI tract associated with a complicated disease outcome?
Methods

Study design
In this large, observational study, we retrospectively analysed prospectively obtained data from the SIBDCS. The SIBDCS started enrolment of IBD patients in 2006 and includes patients from all regions across Switzerland. All patients were diagnosed with IBD according to international guidelines. The SIBDCS is funded by the Swiss National Science Foundation and has been approved by the local ethics committee of each participating centre [institutional review board approval No. EK-1316, approved on February 5, 2007] . All patients had provided written informed consent before inclusion into the SIBDCS.
Study population and data collection
Inclusion criteria for the SIBDCS have been published elsewhere. 24 A thorough clinical and laboratory assessment is performed at the time of inclusion into the study. Patients enrolled in the SIBDCS attend follow-up visits at least once a year. Detailed questionnaires are completed by the patients and the responsible physicians at enrolment and at each follow-up visit. These questionnaires capture clinical, socioeconomic, and psychosocial data. These data are collected and validated by the data centre of the SIBDCS, which follows rigorous rules to ensure data quality. For the purpose of this study, the following inclusion criteria were applied 
Outcome measures and definitions
The following outcome parameters were assessed as possible predictors for the presence of upper GI tract involvement at diagnosis and at any time during the follow-up: gender [ In order to assess whether or not upper GI tract involvement affects disease outcome, the following surrogate markers for a complicated disease course were assessed: presence of bowel strictures, presence of intestinal and perianal fistulas, and need for CD-related intestinal surgery. Patients presenting with at least one of these complications or undergoing at least one type of CD-related intestinal surgery were summarised as having 'any complication'. Intestinal surgery was defined as any of the following interventions: surgery for fistula or abscess, ileal resection, ileo-caecal resection, small bowel resection other than terminal ileum, right or left colectomy, colectomy, proctocolectomy, ileostomy, and colostomy.
Disease location was classified according to the Montreal classification. 3 For CD, L1 denotes disease in the terminal ileum, L2 denotes disease in the colon, L3 denotes ileocolonic disease, and L4 denotes disease in the upper gastrointestinal tract. For the purposes of this study, upper GI tract involvement was defined as follows: i] involvement of oesophagus or stomach; or ii] involvement of duodenum or jejunum [ Supplementary Figure 1] , based on available diagnostic modalities [endoscopy, radiology, or surgery]. Disease duration was defined as the time between CD diagnosis and the beginning of the latest available follow-up period. Current age was defined as age at the beginning of the latest available follow-up period, and current smoking status referred to the smoking status at the beginning of the latest available follow-up period. Diagnostic delay was defined as the time interval from onset of CD-related symptoms to established CD diagnosis. 25 . In a second step, all risk factors with a p-value < 0.1 in the univariate analysis were entered together into the multivariate logistic regression model. Kaplan-Meier estimates were used to compute the cumulative incidence of complications stratified by upper GI tract involvement [yes versus no]. The log-rank test was used to detect overall statistical difference in estimates. Cox proportional hazard analysis was used to examine the association of upper GI tract involvement with occurrence of complications. Patients were censored at the time when first complication occurred, or on December 31, 2016. For the purpose of this study, a p-value of < 0.05 was considered statistically significant.
Statistical analysis
Results
Patient demographics
Of the 1840 CD patients enrolled in the SIBDCS at the time of analysis, we included a total of 1638 CD patients; 202 patients were excluded due to unknown disease location. 
Upper gastrointestinal tract involvement at CD diagnosis
We identified 107 patients with upper GI tract involvement at the time of CD diagnosis, corresponding to 6.5% of the studied CD cohort. Compared with controls with CD without upper GI tract involvement, these patients were more often males [57.9% versus 46.1%, p = 0.017], younger at diagnosis [median 24 versus 27 years, p = 0.027], and showed a trend towards a longer diagnostic delay [median 7 versus 5 years, p = 0.058]; for details see Table 1 . Frequency of upper GI tract involvement at the time of CD diagnosis increased over time. Whereas such involvement was seen in 5.1% of the patients diagnosed between 1955 and 1995, the prevalence of upper GI tract involvement was 11.3% for patients diagnosed between 2009 and 2016 [p = 0.001, Figure 1] 
Impact of upper gastrointestinal tract involvement on CD complications and intestinal surgery
To investigate the impact of upper GI tract involvement on disease course, we analysed the follow-up of all patients with upper GI tract involvement at the time of CD diagnosis and compared them with controls without such involvement. During a median follow-up of Table 5 . Again, no significant differences were seen between patients with upper GI tract involvement compared with controls. Subgroup analyses stratified by demographics and risk factors for occurrence of complications did not show any significant effect modification [Supplementary Patients with oesophageal/stomach involvement even showed a trend towards less complications and fistula development. However, patients with duodenal/jejunal involvement were more likely to undergo intestinal resection in the follow-up compared with non-L4 patients.
Discussion
Although CD most often affects the ileocaecum, CD may actually involve any part of the GI tract. Frequency of upper GI tract involvement has been reported with a large variation. To date and in the era of increasing use of upper endoscopies and early TNF treatment, prevalence rates in a large, nationwide IBD cohort are unknown, and possible risk factors for and the impact of upper GI involvement on future disease course remain largely elusive. We therefore investigated in a large cohort of CD patients: 1] the frequency of upper GI tract involvement at diagnosis and at any time during follow-up; 2] predictive factors associated with the presence of such involvement; and 3] the disease outcome in patients with upper GI tract involvement compared with controls. Upper GI tract involvement was observed in 6.5% of the patients at the time of CD diagnosis and in 13.1% of the patients at any time during the follow-up. Of note, these rates were increasing over time, with 5.1% of the patients showing upper GI involvement at CD diagnosis before 1995, whereas 11.3% of the patients that were diagnosed between 2009 and 2016 had such involvement. The rates reported in our study are considerably lower than those of recent articles including a comprehensive analysis of the NIDDK IBD Genetics Consortium database [rate of 16.4%]. 23 They rather mirror prevalence rates of earlier studies. [13] [14] [15] This is most probably due to the fact that upper endoscopy is not regularly performed at the time of CD diagnosis, if symptoms are not suggestive for upper GI tract involvement. However, increasing rates over the past few decades, with the highest frequency within the past few years, go in line with the ECCO guidelines, which actually recommend-although with very low evidence-such an approach. 1 It has yet to be determined whether the difference between rates at diagnosis versus at any time during the follow-up is due to progressing disease or due to the increasing use of upper endoscopy over time. 1995] were the only factors associated with the presence of upper GI tract involvement at CD diagnosis. This is in accordance with a previous publication by Lazarev and colleagues who demonstrated a higher rate of male patients suffering from L4 compared with non-L4 disease [53% versus 47%, p = 0.02]. 23 Our multivariate logistic regression model makes thede data more robust. The identification of the time point of diagnosis as a predictive factor may be largely attributed to the increasing use of upper endoscopy over time regardless of initial symptoms, as suggested by the current ECCO guidelines. 1 Of note, no other predictive factors were identified in this logistic regression analysis. Neither body mass index [BMI], family history, smoking status, oror diagnostic delay was able to predict upper GI tract involvement at the time of CD diagnosis. However, anti-TNF treatment, and presence of erythema nodosum and oral ulcers were positively associated with upper GI tract involvement at any time, whereas disease duration was negatively associated. The effect of anti-TNF treatment has to be interpreted cautiously; it is actually more likely that patients with upper GI tract involvement have a higher chance of being treated with biologics, given previous data suggesting higher complication rates in these patients, although the latter were not confirmed in our study. The retrospective nature of the analysis does not make it possible to disentangle this relationship.
Disease course of patients with upper GI tract involvement at the time of CD diagnosis does not appear to be significantly different from that of control CD patients. Moreover, patients with upper GI tract involvement seem to show an even better outcome regarding development of intestinal fistulas, which was particularly observed in patients with oesophageal/stomach involvement.
However, a subgroup analysis for patients with duodenal/jejunal involvement revealed an outcome similar to that of non-upper GI tract patients, except for higher rates of intestinal resection. This contrasts with previous findings, which suggested higher rates of complications in L4 patients. It has been previously shown that the L4 phenotype is associated with stricturing disease and abdominal surgery [compared with non-L4 CD]. 23 There are two possible explanations for our results. First, upper GI tract involvement is indeed no risk factor for a complicated disease outcome. This is supported by a Cox regression model stratified by demographics and multiple risk factors without any significant modifying effect on disease outcome in patients with upper GI tract involvement. Second, increased detection of patients with upper GI tract involvement at the time of diagnosis, due to increased use of upper endoscopy over time, may have resulted in over-diagnosis of such involvement considering even minor and particularly asymptomatic involvement as significant. Therefore, its potentially negative effect on disease course may have vanished. Either of our data question the current guidelines, which recommend-based on expert opinion only-upper endoscopy regardless of symptoms. 1 One might argue that increased use of anti-TNF in patients with upper GI tract involvement has resulted in a favourable outcome. However, even after correcting for anti-TNF treatment, outcome of patients with versus without such involvement appears to be the same. In patients never treated with anti-TNF, there was even a trend towards a better outcome with upper GI tract involvement at the time of CD diagnosis. Prospective trials are needed in order to investigate whether or not upper endoscopy and early identification of upper GI tract involvement has its value.
Our study has several strengths and limitations. We analysed a large number of patients [> 1600] in a nationwide IBD cohort. Stringent inclusion and exclusion criteria, close follow-up, and standardised enrolment and follow-up questionnaires completed by both patients and physicians minimised the drawbacks of a retrospective data analysis. In addition, disease location is reported in detail in the Swiss IBD cohort, both at enrolment and during followup. In most of the patients [> 90%], disease location was assessed by endoscopy, although the SIBDCS questionnaire did not capture the number of upper versus lower endoscopies for assessment of disease location. A median follow-up of 5 years makes the outcome analysis of patients with upper GI tract involvement at the time of CD diagnosis, versus controls, more reliable. However, there might be a possible selection bias given the fact that the SIBDCS is not population based. Patients with more severe course [recruited at tertiary referral centres] might be over-represented. Thus, our findings cannot be applied one to one to a general IBD population. It cannot be ruled out that some non-specific endoscopic changes due to non-steroidal anti-infammatory drugs intake or Helicobacter pylori infection were misinterpreted as CD manifestations; therefore the frequency of upper GI tract involvement might have been overestimated. Due to the nature of our study and the reliance on retrospective questionnaires, independent verification of physician`s findings was not feasible. Given the fact that these data are not independent, it was not possible to determine direction of the association between anti-TNF treatment and upper GI tract involvement. A clear limitation is that our questionnaire does not distinguish between duodenal and jejunal disease. Therefore, a separate analysis for jejunal upper GI tract involvement versus non-jejunal upper GI tract involvement was not feasible, although jejunal disease has been previously identified as a risk factor for CD complications. 23 Very lately, both L4 jejunal and L4 proximal ileal disease have been associated with higher rates of intestinal resection. 26 At least we were able to perform subgroup analysis for oesophageal/stomach and duodenal/jejunal involvement. The latter group was more likely to undergo intestinal resection in the follow-up, but there were otherwise no differences in terms of development of future complications in either group compared with non-L4 patients. We defined severe disease course as development of complications in the follow-up only, which is a rather hard outcome. There might be differences between non-L4 and L4 regarding softer outcomes such as seen for erythema nodosum, which was associated with upper GI tract involvement in the follow-up. However, we did not include extraintestinal manifestations in our definition of severe disease.
In conclusion, upper GI tract involvement is frequently observed, and prevalence has been increasing over recent decades, most probably due to an increasing use of screening upper endoscopies. Male sex and young age ≤ 16 years were identified as the main predictive factors for upper GI tract involvement at the time of CD diagnosis. Even after correcting for anti-TNF treatment, patients with upper GI tract involvement at CD diagnosis did not show a worse outcome compared with controls. This questions the current recommendation for screening by upper endoscopy at the time of CD diagnosis, regardless of symptoms. Prospective trials are needed to evaluate the value of such early upper endoscopy.
What is known?
• Frequency of upper gastrointestinal [GI] tract involvement in Crohn`s disease [CD] has been reported with a large variation.
• Risk factors and disease course of patients with upper GI tract involvement remain elusive.
• Current guidelines recommend screening for upper GI tract involvement at the time of CD diagnosis regardless of symptoms, although evidence level is low.
What is new?
• Upper GI tract involvement was observed in 6.5% of patients at the time of CD diagnosis and in 13.1% of patients at any time during the follow-up. 
